Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Echoing the above findings, the mRNA and protein expression of KDM4C was higher in human prostate tumor tissues as compared to adjacent normal prostate tissues, and higher KDM4C protein expression in prostate tumors correlated to higher protein expression level of AKT and c-Myc.
|
31766290 |
2019 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination of Pim and AKT inhibitors resulted in synergistic inhibition of prostate tumor growth in vitro and in vivo.
|
23585456 |
2013 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DHA also inhibits AKT(T308) but not AKT(S473) phosphorylation, alters PI(3,4,5)P3 (PIP3) and phospho-AKT(S473) protein localization, decreases pPDPK1(S241)-AKT and AKT-BAD interaction and suppresses prostate tumor growth.
|
23633519 |
2013 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
PIK3CA, BRAF, KRAS and AKT1 mutations are very infrequent events in prostate tumors.
|
21113138 |
2011 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we identify the AKT-inactivating phosphatase PHLPP1 as a prostate tumor suppressor.
|
21840483 |
2011 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A mutational profiling of AKT1 and of the mutational hotspots in PIK3CA and PIK3R1 was carried out in samples from primary and recurrent prostate tumours.
|
20407443 |
2010 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Western blot analysis indicated that docetaxel-resistant sublines derived from DU145 and PC3 prostate tumor cell lines displayed a markedly increased phospho-AKT level closely accompanied by heightened sCLU expression when compared with parental cells.
|
20501799 |
2010 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Array analyses of transcription in multiple murine prostate tumor models featuring PI3K/AKT pathway activation allowed construction of a pathway signature that may be useful in predicting the prognosis of human prostate tumors.
|
20534477 |
2010 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway.
|
18924134 |
2009 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
|
19116269 |
2009 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
An activating mutation in AKT1 in human prostate cancer.
|
18798258 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
|
18512729 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
|
18776922 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction.
|
17469127 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer.
|
17148458 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells.
|
17584963 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
|
17616684 |
2007 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
|
17606718 |
2007 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms.
|
17823925 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
|
17551921 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3KAkt.
|
17898861 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells.
|
17512923 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract.
|
16820098 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.
|
16543232 |
2006 |